CN111479822A - 靶向lemd1的癌症疫苗和其用途 - Google Patents

靶向lemd1的癌症疫苗和其用途 Download PDF

Info

Publication number
CN111479822A
CN111479822A CN201880080531.2A CN201880080531A CN111479822A CN 111479822 A CN111479822 A CN 111479822A CN 201880080531 A CN201880080531 A CN 201880080531A CN 111479822 A CN111479822 A CN 111479822A
Authority
CN
China
Prior art keywords
seq
nucleic acid
amino acid
acid sequence
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880080531.2A
Other languages
English (en)
Chinese (zh)
Inventor
严健
安娜·斯莱格
布拉德利·加曼
尼尔·库奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inovio Pharmaceuticals Inc
Original Assignee
Inovio Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inovio Pharmaceuticals Inc filed Critical Inovio Pharmaceuticals Inc
Publication of CN111479822A publication Critical patent/CN111479822A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201880080531.2A 2017-12-13 2018-12-13 靶向lemd1的癌症疫苗和其用途 Pending CN111479822A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762598329P 2017-12-13 2017-12-13
US62/598,329 2017-12-13
US201762598612P 2017-12-14 2017-12-14
US62/598,612 2017-12-14
PCT/US2018/065534 WO2019118771A1 (en) 2017-12-13 2018-12-13 Cancer vaccines targeting lemd1 and uses thereof

Publications (1)

Publication Number Publication Date
CN111479822A true CN111479822A (zh) 2020-07-31

Family

ID=66734873

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880080531.2A Pending CN111479822A (zh) 2017-12-13 2018-12-13 靶向lemd1的癌症疫苗和其用途

Country Status (11)

Country Link
US (2) US11338028B2 (https=)
EP (1) EP3724217A4 (https=)
JP (3) JP7314139B2 (https=)
KR (2) KR20240096711A (https=)
CN (1) CN111479822A (https=)
AU (2) AU2018384824B2 (https=)
BR (1) BR112020011620A2 (https=)
CA (1) CA3084137A1 (https=)
MX (2) MX2020006305A (https=)
RU (1) RU2760984C1 (https=)
WO (1) WO2019118771A1 (https=)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229277A1 (en) * 2001-09-18 2004-11-18 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CN1695059A (zh) * 2002-08-30 2005-11-09 肿瘤疗法科学股份有限公司 诊断结肠癌和胃癌的方法
KR20100121949A (ko) * 2009-05-11 2010-11-19 한국생명공학연구원 대장암 및 전이에 대한 바이오마커, 이를 이용한 대장암 진단 및 치료제 스크리닝
CN103890587A (zh) * 2011-08-31 2014-06-25 昂科赛特公司 用于治疗和诊断癌症的方法和组合物
US20140315743A1 (en) * 2011-10-03 2014-10-23 Karen Chapman Methods and Compositions for the Treatment and Diagnosis of Ovarian Cancer
WO2017203526A1 (en) * 2016-05-23 2017-11-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of diagnosing cancer using cancer testis antigens

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1954826A4 (en) 2005-11-27 2010-05-05 Compugen Ltd NEW NUCLEOTIDE AND AMINO ACID SEQUENCES AND TESTS AND METHOD FOR THEIR USE FOR DIAGNOSIS
DK2091965T3 (da) 2006-10-17 2013-08-05 Oncotherapy Science Inc Peptidvacciner mod cancere, der udtrykker MPHOSPH1- eller DEPDC1-polypeptider
PL391627A1 (pl) * 2010-06-25 2012-01-02 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
AU2013243948A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
CA2888648C (en) * 2012-12-13 2021-06-08 The Trustees Of The University Of Pennsylvania Wt1 vaccine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229277A1 (en) * 2001-09-18 2004-11-18 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CN1695059A (zh) * 2002-08-30 2005-11-09 肿瘤疗法科学股份有限公司 诊断结肠癌和胃癌的方法
KR20100121949A (ko) * 2009-05-11 2010-11-19 한국생명공학연구원 대장암 및 전이에 대한 바이오마커, 이를 이용한 대장암 진단 및 치료제 스크리닝
CN103890587A (zh) * 2011-08-31 2014-06-25 昂科赛特公司 用于治疗和诊断癌症的方法和组合物
US20140315743A1 (en) * 2011-10-03 2014-10-23 Karen Chapman Methods and Compositions for the Treatment and Diagnosis of Ovarian Cancer
WO2017203526A1 (en) * 2016-05-23 2017-11-30 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods of diagnosing cancer using cancer testis antigens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DAISUKE YUKI等: "Isolation of LEM domain-containing 1, a novel testis-specific gene expressed in colorectal cancers" *

Also Published As

Publication number Publication date
US11338028B2 (en) 2022-05-24
EP3724217A1 (en) 2020-10-21
KR20200096959A (ko) 2020-08-14
AU2018384824B2 (en) 2022-08-04
AU2018384824A8 (en) 2020-07-30
AU2022263546A1 (en) 2022-12-08
US20190175712A1 (en) 2019-06-13
JP2025065334A (ja) 2025-04-17
RU2760984C1 (ru) 2021-12-02
EP3724217A4 (en) 2022-01-12
CA3084137A1 (en) 2019-06-20
JP2023111915A (ja) 2023-08-10
US20220265800A1 (en) 2022-08-25
KR102673699B1 (ko) 2024-06-17
MX2024005404A (es) 2024-08-06
JP7633306B2 (ja) 2025-02-19
WO2019118771A1 (en) 2019-06-20
MX2020006305A (es) 2020-09-17
KR20240096711A (ko) 2024-06-26
BR112020011620A2 (pt) 2020-12-08
JP2021506264A (ja) 2021-02-22
JP7314139B2 (ja) 2023-07-25
AU2018384824A1 (en) 2020-07-16

Similar Documents

Publication Publication Date Title
KR101255419B1 (ko) 인플루엔자 바이러스의 다중 아형에 대한 신규 백신
KR102742526B1 (ko) 암 백신 및 이를 이용하는 치료 방법
US20220265800A1 (en) Cancer vaccines targeting lemd1 and uses thereof
JP2023155245A (ja) サバイビンを標的とするがんワクチンおよびその使用
KR102216078B1 (ko) 유전자 백신으로 사용하기 위한 항원 유전자 전달용 발현 벡터 및 이를 포함하는 유전자 백신
HK40034680A (en) Cancer vaccines targeting lemd1 and uses thereof
KR20200140799A (ko) 호흡기 세포융합 바이러스에 대하여 사용하기 위한 핵산 항체 작제물
JP7554320B2 (ja) メソセリンを標的とするがんワクチンおよびその使用
US12161706B2 (en) Cancer vaccines targeting BORIS and uses thereof
BR112020010542A2 (pt) moléculas de ácido nucleico, vetor, composição, proteínas, usos dos anteriores, e vacinas
HK1262085A1 (en) Cancer vaccines and methods of treatment using the same
HK40044253A (en) Nucleic acid antibody constructs for use against respiratory syncytial virus
HK40034677A (en) Cancer vaccines targeting mesothelin and uses thereof
HK1149176B (en) Vaccines against multiple subtypes of influenza virus

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40034680

Country of ref document: HK